基石药业(02616.HK)发表阿泊替尼之桥接研究初步结果
基石药业(02616.HK)公布,在2020年中国临床肿瘤协会学术年会上公布了抗肿瘤药物Avapritinib(阿泊替尼)在中国I/II期桥接不可切除或转移性胃肠道间质瘤(「GIST」)研究用於治疗患者取得的积极结果。阿泊替尼由基石药业全球合作夥伴Blueprint Medicines开发。
研究显示阿泊替尼在中国GIST患者中耐受性良好,并证明该药对携带PDGFRA D842V突变的中国患者具有很强的抗肿瘤活性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.